Drugs / KCAT19 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05391490 | Oct 2022 → Nov 2024 overdue | hematopoietic and lymphoid system neoplasm | University College, London | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KCAT19 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05391490 ↗ |
| Modality | Cell therapy | “allogeneic cord-blood derived T cells” NCT05391490 ↗ |
| Route | Intravenous | “The KCAT19 T cells are given as an intravenous infusion.” NCT05391490 ↗ |
| Target | CD19 | “a target protein (CD19) present on the surface of the malignant B-cells” NCT05391490 ↗ |